evitria AG

Are you attending PEGS Europe 2024? We are excited to announce that evitria will be participating in this premier event, dedicated to protein and antibody engineering. At PEGS Europe, our team will be on-site to share insights into how we at evitria are advancing the field of therapeutic antibodies, particularly in bispecific antibody production. Whether you are developing new therapies or refining existing strategies, we look forward to discussing how our capabilities can support your projects. 📅 Dates: November 5-7, 2024 📍 Location: Barcelona, Spain If you are attending, don’t miss the opportunity to connect with us. Visit our booth or schedule a meeting in advance. Let’s explore how we can work together to push the boundaries of protein and antibody engineering. Looking forward to seeing you in Barcelona!

Continuing our series on FDA-approved antibodies, this week we focus on Bevacizumab (Avastin), approved in 2004. 🔬 Antibody type: Humanized IgG1 💊 Brand name: Avastin 🏢 Company: Genentech 🎯 First indication: Colorectal cancer Bevacizumab is a pioneering therapy that targets vascular endothelial growth factor (VEGF), a protein that promotes the growth of new blood vessels. By inhibiting VEGF, Avastin effectively starves tumors of the blood supply they need to grow and spread. This innovative approach has made Bevacizumab a cornerstone in the treatment of several types of cancer, including metastatic colorectal cancer and non-small cell lung cancer. Its ability to inhibit angiogenesis has opened new avenues in cancer therapy. Join us next week, as we continue to explore groundbreaking FDA-approved antibodies! #AntibodyOfTheWeek #FDAApproved #MonoclonalAntibodies #CancerTreatment #AngiogenesisInhibition #Biotechnology #MedicalInnovation

In our ongoing series on FDA-approved antibodies, this week we shine the spotlight on Adalimumab (Humira), approved in 2002. 🔬 Antibody type: Human IgG1 💊 Brand name: Humira 🏢 Rights: AbbVie Inc. 🎯 First indication: Rheumatoid arthritis Adalimumab is a fully human monoclonal antibody that targets tumor necrosis factor-alpha (TNF-α), a cytokine involved in systemic inflammation. By binding to TNF-α, Adalimumab reduces inflammation and modulates the immune response, providing relief for a variety of autoimmune conditions. Humira has been a groundbreaking therapy, offering patients suffering from chronic inflammatory diseases a chance to manage their symptoms more effectively. Its broad range of approved indications, from rheumatoid arthritis to Crohn’s disease and beyond, highlights its versatility and importance in modern medicine. Adalimumab has transformed the lives of millions, setting a high standard for biologic therapies in the treatment of autoimmune diseases. #AntibodyOfTheWeek #FDAApproved #MonoclonalAntibodies #AutoimmuneDisease #Humira #Biotechnology #MedicalInnovation

🎉 A big thank you to our 3,000 followers! 🎉 We’re thrilled to have reached 3,000 followers and are grateful to each of you for being part of the evitria community. As we continue to grow, we’re more committed than ever to sharing meaningful insights and keeping you informed on the latest developments in antibody research. Moving forward, you can expect: • Weekly papers in our evitria Journal Club • Updates on antibody development strategies • Exclusive video content and case study downloads We’re excited about what’s to come and will continue working hard to bring you valuable content and stay on top of the latest advancements. Thank you for your ongoing support—we couldn’t do it without you! #ThankYou #3000Followers #AntibodyResearch #Innovation #evitria

evitria’s journal club - paper of the week no. 43 Targeting cytokine and chemokine signaling pathways for cancer therapy Ming Yi et al (Jul 2024) 🌟 New Insights in Cancer Therapy 🌟 Exciting advancements in targeting cytokine and chemokine signaling pathways for cancer treatment! This review highlights the dual roles of cytokines in tumor growth and suppression, and explores innovative therapies like bispecific antibodies and receptor inhibitors. Combining these with existing treatments could revolutionize cancer care. Stay tuned for more breakthroughs in immunotherapy! 💪🔬 Developing a new therapeutic? Get in touch with our scientists to learn how we can support you: www.evitria.com/contact #Biotech #AntibodyEngineering #AntibodyTherapeutics

Explore the applications of bispecific antibodies in therapeutics. 🧫 In his new article, Desmond Schofield delves into how bispecific antibodies are currently being utilized in various therapeutic areas and their potential for future applications. Learn how these versatile tools are making a difference in medical treatments. Check out the article: https://lnkd.in/dgEyDCCG #BispecificAntibodies #DrugDiscovery #Oncology #Cancerresearch

This week in our series on FDA-approved antibodies, we're excited to feature Cetuximab (Erbitux), approved in 2004. 🔬 Antibody type: Chimeric IgG1 💊 Brand name: Erbitux 🏢 Manufacturer: Eli Lilly and Company and Merck KGaA, Darmstadt, Germany 🎯 First indication: Colorectal cancer Cetuximab targets the epidermal growth factor receptor (EGFR), inhibiting cell growth and inducing apoptosis in cancer cells. It’s used to treat metastatic colorectal cancer and squamous cell carcinoma of the head and neck. Erbitux was a significant advancement in cancer therapy, providing a targeted approach to inhibit tumor growth and improve patient outcomes. #AntibodyOfTheWeek #FDAApproved #MonoclonalAntibodies #CancerTreatment #ColorectalCancer #Biotechnology #MedicalInnovation

🔬 New article out now! Discover our latest piece, ''Types of bispecific Antibodies: Exploring the Diverse Formats in Therapeutic Development,'' where we examine the various bispecific antibody formats and their applications. Want to understand the different formats and their uses in therapy? Click below to read more. https://lnkd.in/euNFwG65 #BispecificAntibodies #Immunotherapy #DrugDiscovery #Oncology #Cancerresearch

In our series on FDA-approved antibodies, this week we highlight Efalizumab (Raptiva), approved in 2003. 🔬 Antibody type: Humanized IgG1 💊 Brand name: Raptiva 🏢 Company: Genentech and Merck Serono 🎯 First indication: Psoriasis Status: discontinued Efalizumab targets the CD11a subunit of LFA-1 on T cells, inhibiting the interaction with ICAM-1, and reducing inflammation and cell proliferation in psoriasis. It was a groundbreaking treatment for patients with moderate to severe plaque psoriasis. Though withdrawn in 2009 due to safety concerns, Efalizumab's development contributed significantly to the understanding and advancement of targeted therapies for autoimmune diseases. Stay tuned for our next post on another FDA-approved antibody! #AntibodyOfTheWeek #FDAApproved #MonoclonalAntibodies #Psoriasis #Biotechnology #MedicalInnovation

Only 2 days left until the Festival of Biologics in Basel! We’re gearing up for an exciting event, where the latest in immunotherapy, antibodies, and biosimilars will be in focus. Visit us at booth #900 to discuss how evitria’s expertise can support your therapeutic projects. Looking forward to connecting with industry peers and driving innovation together! ⭐